PDCD1 and melanoma: Emerging clinical observations are reporting neurological complications associated with treatment using anti-CTLA-4 and anti-PD-1 in patients with melanoma, lung cancers, and Merkel-cell carcinoma at five weeks post-therapy [6, 19, 20].